Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab with tremelimumab for limited stage small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2019 View  |  Download
Durvalumab with gemcitabine-cisplatin neoadjuvant treatment and durvalumab adjuvant treatment for muscle-invasive bladder cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
Durvalumab with fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer 5-Fluorouracil , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Leucovorin , Oxaliplatin Gastro-oesophageal junction cancer Gastrointestinal Cancer 2023 View  |  Download
Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer Carboplatin (Paraplatin) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Paclitaxel (Taxol; paclitaxel albumin) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Ovarian cancer Female Reproductive Cancer 2023 View  |  Download
Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab with Bacillus Calmette-Guerin for treating non-muscle invasive bladder cancer Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
1 2 82 83 84 85 86 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications